The International Collaborative Study of Maternal Phenylketonuria status report 1998

• Published in: Mental retardation and developmental disabilities research reviews Vol. 5; no. 2; pp. 117 - 121
• Main Authors: Koch, R., Friedman, E., Azen, C., Hanley, W., Levy, H., Matalon, R., Rouse, B., Trefz, F., Waisbren, S., Michals-Matalon, K., Acosta, P., Güttler, F., Ullrich, K., Platt, L., de la Cruz, F.
• Format: Journal Article
• Language: English
• Published: New York John Wiley & Sons, Inc 1999
• Subjects: congenital heart disease; Maternal Phenylketonuria Collaborative Study; phenylalanine; phenylketonuria; Wechsler Adult Intelligence Quotient-Revised (WAIS-R); Wechsler Intelligence Quotient-Revised (WISC-R)
• ISSN: 1080-4013; 1098-2779
• DOI: 10.1002/(SICI)1098-2779(1999)5:2<117::AID-MRDD4>3.0.CO;2-W

The Maternal PKU Study began in 1984 and during the intervening years, 572 pregnancies in women with hyperphenylalaninemia (HPA) and 99 controls and their outcomes have been evaluated. Among Women with HPA who delivered a live infant, only 15.9% were treated and in metabolic control preconceptionally; however, another 18.4% were in control by 10 weeks. Compared to the results reported by Lenke and Levy in 1980, there is a marked improvement in outcome with treatment. Microcephaly was unusual in preconceptionally treated pregnancies with well‐controlled phenylalanine‐restricted diets. Even in pregnancies that established control after conception but before the 8th week, congenital heart disease did not occur in the offspring; however, it did occur in 12% of pregnancies not achieving control until after 10 weeks of pregnancy. The recommended level of blood phenylalanine during pregnancy is 120–360 μmol/L. Best results were obtained by close cooperation between the attending obstetrician and a metabolic team experienced in the care of persons with phenylketonuria. MRDD Research Reviews 1999;5:117–121. © 1999 Wiley‐Liss, Inc.